Psychedelic Stocks Surge After Trump Urges FDA for Faster Reviews

• Major gainers include ATAI Life Sciences (+26%), Compass Pathways (+24%), and GH Research (+17%) as the order provides 'official stamp of validation' to the psychedelic drug class
• The order directs FDA to grant Commissioner's National Priority Vouchers to breakthrough psychedelic therapies, potentially enabling approval decisions as soon as summer 2026
• Trump committed $50 million in federal funding for ibogaine research, a Schedule I substance being studied for PTSD, depression, and addiction treatment

Summary: Psychedelic Stocks Surge After Trump Urges FDA for Faster Reviews

Key Development:

Psychedelic drug stocks surged in premarket trading on April 20, following President Trump's executive order directing the FDA to accelerate reviews of psychedelic therapies and increase federal research funding.

Market Performance:

• ATAI Life Sciences jumped 26%
• Compass Pathways climbed 24%
• GH Research gained 17%
• Definium Therapeutics rose 14%
• Mind Medicine and other sector stocks increased 5-15%

Policy Details:

The executive order, issued Saturday, instructs the FDA to fast-track reviews of psychedelic treatments, particularly ibogaine, which is being studied for PTSD, depression, and addiction. The order directs the agency to grant Commissioner's National Priority Vouchers to psychedelic drugs with "breakthrough therapy" designation, potentially reducing review times from 6-10 months to just 1-2 months. FDA Commissioner Marty Makary indicated decisions could come as soon as summer 2026.

Funding:

Trump allocated $50 million in federal research funding specifically for ibogaine studies.

Market Implications:

Analysts view the order as significant validation for the sector. Jefferies analyst Andrew Tsai called it an "official stamp of validation," while RBC's Brian Abrahams noted it represents "a substantial step towards diminishing regulatory risk."

Context:

Ibogaine, derived from an African shrub, is currently classified as a Schedule I substance with no accepted medical use. Health Secretary Robert F. Kennedy Jr. has championed psychedelic alternatives for mental health treatment, with bipartisan congressional support for expanding access to these therapies.